Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

deCode's survival is vital for genetic research

This article was originally published in Clinica

Executive Summary

deCode Genetics, a leading biomarker discovery company under its CEO Kari Stefansson, seems to be stuck between the devil and the deep blue sea. Either it sells its profit-making drug development outlets in the US to safeguard its leading complex traits genetics operations, only to face a very uncertain future in a diagnostics market that hasn’t quite made the transition into the personalised medicine world; or it faces an extremely rough ride in the current economic maelstrom, which has had particularly sharp repercussions in Iceland. The only way out seems to be a takeover by a well-heeled investor willing to preserve the company’s unique position of trust among Iceland’s population.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel